News

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion
Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Stock Movers: LMT, COP, Eli Lilly
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
pharmaphorum2h
Is Lilly about to swoop on Verve Therapeutics?
In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...
Lilly to offer highest doses of weight-loss drug Zepbound on website
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Lilly to Offer Higher Dose Versions of Weight-Loss Drugs on Website
(Reuters) -U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug ...
Fierce Pharma21h
Eli Lilly adds high-dose Zepbound options to lineup of cheaper vials available on self-pay website
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...